Wednesday, November 01, 2023
iSTAR Medical, a leading medtech company focused on delivering innovative solutions for eye care, has made a significant announcement today. The company has successfully performed the first MINIject® implant surgeries in Ireland, marking an important step in the expansion of its minimally-invasive glaucoma surgery (MIGS) device throughout Europe.
Glaucoma stands as a prominent cause of blindness in Ireland, and its incidence is predicted to increase by 33% over the next decade. The availability of MINIject® as a treatment option for open-angle glaucoma in Ireland represents a major breakthrough, offering patients a range of advantages compared to traditional treatment methods. As the only commercially available supraciliary MIGS implant, MINIject® has demonstrated a consistent and safe performance record.
The successful implantation of MINIject® at the Institute of Eye Surgery (IOES) is a significant achievement in the advancement of glaucoma treatment in Ireland. This innovative glaucoma implant effectively and safely reduces intraocular pressure (IOP) while targeting a new drainage pathway. This development empowers patients to reduce their reliance on medication and preserve their vision for a longer period. The ongoing expansion of MINIject® across Ireland underlines iSTAR Medical's commitment to enhancing the lives of glaucoma patients around the world.